These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8869469

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
    Dimichele D.
    Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
    [Abstract] [Full Text] [Related]

  • 4. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D, Kroner B, Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [Abstract] [Full Text] [Related]

  • 5. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
    Ettingshausen CE, Kreuz W.
    Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
    [Abstract] [Full Text] [Related]

  • 6. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM.
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 9. Novel therapies for immune tolerance in haemophilia A.
    Collins PW.
    Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [Abstract] [Full Text] [Related]

  • 10. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P, Plamenová I, Hollý P, Stasko J.
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [Abstract] [Full Text] [Related]

  • 11. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.
    Mariani G, Ghirardini A, Bellocco R.
    Thromb Haemost; 1994 Jul; 72(1):155-8. PubMed ID: 7974364
    [Abstract] [Full Text] [Related]

  • 12. Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little.
    Aledort LM.
    Semin Thromb Hemost; 2000 Jul; 26(2):189-93. PubMed ID: 10919412
    [Abstract] [Full Text] [Related]

  • 13. Hemophilia treatment. Immune tolerance induction: prospective clinical trials.
    Hay CR.
    Haematologica; 2000 Oct; 85(10 Suppl):52-5; discussion 55-6. PubMed ID: 11187872
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The treatment of factor VIII inhibitors--a general overview.
    White GC, Roberts HR.
    Vox Sang; 1996 Oct; 70 Suppl 1():19-23. PubMed ID: 8869464
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G, Spranger T, Brackmann HH.
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [Abstract] [Full Text] [Related]

  • 18. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM, Sasgary M, Ahmad RU, Auer W, Turecek PL, Schwarz HP.
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A, Kavakli K, Baytan B, Kazanci E, Sayli T, Oren H, Celkan T, Gursel T.
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.